Saturday 17 October 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.43
0.07
−4.67%
Follow ZYBT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 1.11 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 14.30 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 278 | 277 | 269 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.10 | 0.09 | 0.06 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 29 | 26 | 17 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 61.35 | 48.99 | 20.51 | |||||
| EBT | — | — | — | — | — | — | — | 6 | 2 | (10) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 20.67 | 7.73 | (61.78) | |||||
| Net income | — | — | — | — | — | — | — | 5 | 2 | (12) | |||||
| Depreciation | — | — | — | — | — | — | — | 3 | 3 | 4 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.64 | 0.56 | 0.35 | ||||
| Earnings | — | — | — | — | — | — | — | 0.11 | 0.03 | (0.21) | |||||
| Cash flow | — | — | — | — | — | — | — | 0.15 | 0.12 | 0.04 | |||||
| Capex | — | — | — | — | — | — | — | (0.03) | (0.08) | (0.04) | |||||
| Free cash flow | — | — | — | — | — | — | — | 0.11 | 0.04 | 0.00 | |||||
| Book value | — | — | — | — | — | — | — | 1.02 | 1.06 | 0.93 | |||||
| Shares, m | — | — | — | — | — | — | — | 46 | 46 | 47 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.61 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 7 | 6 | 2 | ||||
| Capex | — | — | — | — | — | — | — | (1) | (4) | (2) | |||||
| Free cash flow | — | — | — | — | — | — | — | 5 | 2 | 0 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 8 | 6 | 2 | ||||
| Total debt | — | — | — | — | — | — | — | 12 | 12 | 11 | |||||
| Net debt | — | — | — | — | — | — | — | 8 | 9 | 3 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 47 | 48 | 44 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | 2.27 | (15.36) | ||||
| ROIC | — | — | — | — | — | — | — | 7.02 | 2.45 | (13.38) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 3.26 | (21.66) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025
Charts ten years each
Zhengye Biotechnology Holding Limited vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CTOR Citius Oncology, Inc. | $69.4M | — (loss-making) | — | — | n/m | 0.00% | 67.07% | (583.53%) | Compare |
| TLPH Talphera, Inc. | $55.5M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −33.11% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| INCR InterCure Ltd. | $55.1M | 8.8× | — (loss-making) | −6.53% (below 0%: shrinking) | n/m | +389.50% (above 0%: growing) | 32.04% | 0.00% | Compare |
| ZYBT Zhengye Biotechnology Holding Limited | $44.6M | — | — | — | — | −69.31% (below 0%: shrinking) | — | — | |
| SCYX SCYNEXIS, Inc. | $38.9M | — (loss-making) | — (loss-making) | −8.56% (below 0%: shrinking) | n/m | −98.60% (below 0%: shrinking) | 100.00% | (3,308.51%) | Compare |
| IXHL Incannex Healthcare Inc. | $36.1M | — (loss-making) | — (loss-making) | −92.31% (below 0%: shrinking) | n/m | +327.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| RMTI Rockwell Medical, Inc. | $32.2M | — (loss-making) | — (loss-making) | +10.63% (above 0%: growing) | n/m | −12.92% (below 0%: shrinking) | 18.24% | (5.97%) | Compare |
| CPHI China Pharma Holdings, Inc. | $31.3M | — (loss-making) | — (loss-making) | −7.56% (below 0%: shrinking) | n/m | −113.57% (below 0%: shrinking) | 8.82% | (150.99%) | Compare |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $26.5M | 0.2× | — | — | n/m | +82.01% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $37.5M | — | — | −8.06% | — | −6.46% | 49.56% | (2.98%) |
Zhengye Biotechnology Holding Limited (ZYBT) key facts
- Concern: Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
- Concern: Zhengye Biotechnology Holding Limited reported a net loss of $11.9 million, or a loss of $0.21 per share, for fiscal 2025.
- Zhengye Biotechnology Holding Limited (ZYBT) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ZYBT traded at $1.43, a market capitalization of $44.6 million.
- Return on equity was −21.7% and debt-to-equity 0.24.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 1.47 (distress zone) for fiscal 2025.